It helps reduce stress and anxiety while promoting relaxation without drowsiness, making it a favorite among those seeking a natural way to unwind
A systematic review ScienceDirect science/article/pii/S2214623724000048 [6] Emerging pharmacotherapies for obesity: A systematic review ScienceDirect science/article/pii/S0031699724000024 [7] Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials PubMed pubmed.ncbi.nlm.nih.gov [8] Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting PubMed pubmed.ncbi.nlm.nih.gov [9] Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients ScienceDirect science/article/abs/pii/S0146280624000422 [10] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect science/article/pii/S2589537024003614 [11] Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials PubMed pubmed.ncbi.nlm.nih.gov [12] Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting PubMed pubmed.ncbi.nlm.nih.gov [13] Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design PubMed pubmed.ncbi.nlm.nih.gov [14] Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial PubMed pubmed.ncbi.nlm.nih.gov [15] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect science/article/pii/S2589537024003614 [16] Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials ScienceDirect science/article/pii/S2667368125000063 [17] Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis ScienceDirect science/article/pii/S0753332224000313 [18] GLP-1 physiology informs the pharmacotherapy of obesity ScienceDirect science/article/pii/S2212877821001988 [19] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect science/article/pii/S2589537024003614 [20] Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials ScienceDirect science/article/pii/S2667368125000063 [21] The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines PubMed pubmed.ncbi.nlm.nih.gov [22] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [23] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes PubMed pubmed.ncbi.nlm.nih.gov [24] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [25] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect science/article/pii/S2667368124000299 [26] Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis PubMed pubmed.ncbi.nlm.nih.gov [27] Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis PubMed pubmed.ncbi.nlm.nih.gov [28] The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines PubMed pubmed.ncbi.nlm.nih.gov [29] GLP-1 physiology informs the pharmacotherapy of obesity ScienceDirect science/article/pii/S2212877821001988 [30] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist, a step forward in treating diabetes and obesity
Shepard 2014
A better question is: What biological pathway are we trying to influence, and what evidence supports using a specific peptide for that goal? This becomes especially important when comparing BPC-157 and CJC-1295
